share_log

C4 Therapeutics | 10-Q: Q1 2024 Earnings Report

SEC ·  May 8 07:13

Summary by Moomoo AI

C4 Therapeutics (C4T) has reported significant developments in its collaboration agreements with Roche, Biogen, and Calico, focusing on the research, development, and commercialization of novel treatments using the company's proprietary TORPEDO platform. Under the amended Roche Agreement, C4T received an upfront payment of $40 million and may receive increased royalties and reimbursement for commercialization costs if it opts into co-development rights. Roche has the option to license and commercialize products for two targets, with potential milestone payments to C4T up to $273 million per target and sales-based milestone payments up to $150 million per target. The Biogen Agreement, which concluded its research term as of March 31, 2024, involved collaboration on treatments for neurological conditions. C4T received a $45 million upfront payment and is eligible for up to...Show More
C4 Therapeutics (C4T) has reported significant developments in its collaboration agreements with Roche, Biogen, and Calico, focusing on the research, development, and commercialization of novel treatments using the company's proprietary TORPEDO platform. Under the amended Roche Agreement, C4T received an upfront payment of $40 million and may receive increased royalties and reimbursement for commercialization costs if it opts into co-development rights. Roche has the option to license and commercialize products for two targets, with potential milestone payments to C4T up to $273 million per target and sales-based milestone payments up to $150 million per target. The Biogen Agreement, which concluded its research term as of March 31, 2024, involved collaboration on treatments for neurological conditions. C4T received a $45 million upfront payment and is eligible for up to $35 million per target in development milestones and $26 million per target in sales-based payments from Biogen. The Calico Agreement, which ended in March 2023, focused on diseases of aging, including cancer, with potential payments to C4T up to $132 million in development and commercial milestones per target, and up to $65 million in sales-based payments per target. Financially, C4T's revenue from collaboration agreements for the quarter ending March 31, 2024, was $3.039 million, a decrease from $3.759 million in the same period in 2023. The company's financial position includes $13.599 million in accounts receivable and $55.848 million in deferred revenue. C4T continues to advance its clinical trials, including its most advanced product candidates, cemsidomide (CFT7455) for multiple myeloma and non-Hodgkin lymphomas, and CFT1946 for BRAF V600X mutant solid tumors.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more